QuiO adds MedCrypt data security to Smartinjector pen

MedCrypt and QuiO said earlier this month that the companies are partnering to integrate MedCrypt’s data security software into QuiO’s Smartinjector devices.

According to the agreement, MedCrypt will provide software security for QuiO’s Si One pen for specialty drugs and the Si Pen for diabetes patients. The companies plan to integrate the devices with software that can monitor real-time dosing data for suspicious behavior, like unusual dose amounts. The software also enables devices to sign and encrypt data communicated through QuiO’s cloud platform ConnectedRx.

“It’s critical that our bi-directional communication channel remains secure at all times, from both a privacy and safety standpoint,” QuiO co-founder and CEO Alexander Dahmani said in prepared remarks. “We’re proud to be working with MedCrypt, because their technology has been successfully used to secure some of the highest-risk medical devices in the market and we want every available defense in today’s evolving cybersecurity landscape.”

MedCrypt’s technology also includes a machine-learning-based behavior analysis system, which can familiarize itself with a device’s usual usage patterns and flag unusual deviations in dose patterns.

For example, if a surgical robot receives 10,000 instructions each day on average, but suddenly it receives 1 million instructions from a unfamiliar IP address, the system would flag that as a deviation, MedCrypt co-founder and CEO Mike Kijewski said in an interview with Medgadget.

“We are looking forward to making data security a priority in the product development process for QuiO and similarly-staged companies,” MedCrypt co-Founder and CEO Mike Kijewski added. “Smartinjector devices have the ability to reduce medical costs for patients and give them a portable therapy device they can take with them anywhere. As the bi-directional flow of data intensifies, we want to ensure accuracy and safety at every step.”

In October, QuiO raised $1.1 million in a seed round led by undisclosed investors to finish developing its smart injection device, prepare for pilot studies and an FDA 510(k) submission.